Search | Clinical Trials Finder

Conditions: HIV-1-infection
Interventions: Care Navigator, Multicomponent HIV Service Package; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: New York, New York • Queens, New York

Conditions: HIV Infections
Interventions: Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Miami, Florida

Conditions: HIV Infections
Interventions: TUTI-16 (1.0 mg), Placebo; Biological · Other
Lead sponsor: Thymon, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Tenofovir gel, Tenofovir gel placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: CI-1012; Drug
Lead sponsor: Parke-Davis; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Palm Springs, California • San Francisco, California • Maitland, Florida + 1 more

Conditions: HIV Infections, Hepatitis C, Liver Disease
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more

Conditions: HIV-1 Infected Adults With Controlled Viremia
Interventions: VRC-HIVAAV070-00-GT (AAV8-VRC07); Genetic
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1-infection
Interventions: no intervention; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 100 Years
Enrollment: 565 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: The Immune Response Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Anal Neoplasm
Interventions: VGX-3100, CELLECTRA™ 5PSP; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: HIV Infections
Interventions: TUTI-16 (0.2mg), TUTI-16 (1.0 mg); Biological
Lead sponsor: Thymon, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: SB-728-T, Expanded unmodified autologous CD4+ T cells; Biological
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: VH4011499, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: HIV-1-infection
Interventions: 3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 45 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Seattle, Washington

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 3,669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 91
States / cities: Mill Valley, California • Oakland, California • San Francisco, California + 31 more

Conditions: HIV-1 Infection, Hepatitis
Interventions: Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: HIV Infections
Interventions: DTG 50 mg, RPV 25 mg, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more

Conditions: HIV Infections
Interventions: Recombinant interleukin-2 (rIL-2); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 78
States / cities: Los Angeles, California • Mill Valley, California • Oakland, California + 33 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Maraviroc (UK-427,857), Optimized Background Therapy, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 20
States / cities: Sacramento, California • San Francisco, California • Auroa, Colorado + 14 more

Conditions: HIV
Interventions: FP conjugate vaccine (25 mcg), FP conjugate vaccine (200 mcg), Trimer 6931 (100 mcg), Trimer 6931 (200 mcg), Trimer 4571 (200 mcg), Trimer 4571 (100 mcg); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more

Conditions: HIV
Interventions: VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV
Interventions: Not listed
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Foster City, California

Conditions: Human Immunodeficiency Virus Type 1
Interventions: TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 9
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more

Search by objective public record fields.

Ending the Epidemic Interventions in the Dental Setting - UH3

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

A Study of CI-1012 in HIV-Infected Patients

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial

Longer-Acting PrEP in Transgender and Gender Diverse Texans

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects

CCR5-modified CD4+ T Cells for HIV Infection

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

A Study of the Long-Term Outcomes of HIV-Positive Patients

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines